$1.59 Billion is the total value of Bain Capital Life Sciences Investors, LLC's 26 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 54.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SWTX | SPRINGWORKS THERAPEUTICS INC | $528,040,000 | +52.1% | 7,281,307 | 0.0% | 33.15% | +2.5% | |
| AVIR | New | ATEA PHARMACEUTICALS, INC. | $234,622,000 | – | 5,615,659 | +100.0% | 14.73% | – |
| ARQT | ARCUTIS BIOTHERAPEUTICS, INC. | $111,937,000 | -4.0% | 3,979,292 | 0.0% | 7.03% | -35.3% | |
| MRSN | MERSANA THERAPEUTICS | $91,689,000 | +42.9% | 3,445,667 | 0.0% | 5.76% | -3.7% | |
| ANNX | ANNEXON INC | $81,138,000 | -17.2% | 3,241,628 | 0.0% | 5.09% | -44.2% | |
| DRNA | Sell | DICERNA PHARMACEUTICALS INC | $67,858,000 | -7.6% | 3,080,237 | -24.5% | 4.26% | -37.7% |
| SYRS | New | SYROS PHARMACEUTICALS, INC. | $62,768,000 | – | 5,785,036 | +100.0% | 3.94% | – |
| CCCC | New | C4 THERAPEUTICS, INC. | $54,406,000 | – | 1,642,209 | +100.0% | 3.42% | – |
| SLDB | Buy | SOLID BIOSCIENCES INC | $53,517,000 | +581.1% | 7,060,353 | +82.4% | 3.36% | +359.0% |
| New | DYNAVAX TECHNOLOGIES CORP | $48,486,000 | – | 10,895,773 | +100.0% | 3.04% | – | |
| NRIX | NURIX THERAPEUTICS, INC. | $42,228,000 | -5.8% | 1,284,314 | 0.0% | 2.65% | -36.6% | |
| CNST | CONSTELLATION PHARMACEUTICALS, INC. | $40,320,000 | +42.2% | 1,400,000 | 0.0% | 2.53% | -4.3% | |
| APTX | Buy | APTINYX INC | $30,765,000 | +63.8% | 8,891,758 | +60.0% | 1.93% | +10.3% |
| KYMR | Sell | KYMERA THERAPEUTICS INC. | $29,735,000 | +26.1% | 479,605 | -34.3% | 1.87% | -15.0% |
| AGLE | AEGLEA BIO THERAPEUTICS | $21,249,000 | +11.0% | 2,700,000 | 0.0% | 1.33% | -25.2% | |
| MRNS | Sell | MARINUS PHARMACEUTICALS INC | $17,459,000 | -5.1% | 1,431,058 | -0.0% | 1.10% | -36.1% |
| CRNX | CRINETICS PHAMACEUTICALS | $15,118,000 | -10.0% | 1,071,428 | 0.0% | 0.95% | -39.4% | |
| RACA | THERAPEUTICS ACQUISITION COR | $13,920,000 | -3.2% | 1,000,000 | 0.0% | 0.87% | -34.8% | |
| ARYA | ARYA SCIENCES ACQUISITION CORP III | $10,850,000 | +0.3% | 1,000,000 | 0.0% | 0.68% | -32.4% | |
| XFOR | X4 PHARMACEUTICALS INC | $10,600,000 | -5.0% | 1,648,485 | 0.0% | 0.66% | -36.1% | |
| SVRA | SAVARA INC | $5,898,000 | -74.3% | 5,128,593 | 0.0% | 0.37% | -82.7% | |
| BCTG | BCTG ACQUISITION CORP | $5,720,000 | +10.4% | 500,000 | 0.0% | 0.36% | -25.7% | |
| BLSA | New | BCLS ACQUISITION CORP | $5,431,000 | – | 487,500 | +100.0% | 0.34% | – |
| FLACU | New | FRAZIER LIFESCIENCES ACQUISITION CORPunit 12/09/2025 | $3,114,000 | – | 300,000 | +100.0% | 0.20% | – |
| JYAC | New | JIYA ACQUISITION CORP | $3,090,000 | – | 300,000 | +100.0% | 0.19% | – |
| HLXA | New | HELIX ACQUISITION CORP | $2,843,000 | – | 250,000 | +100.0% | 0.18% | – |
| PANAU | Exit | PANACEA ACQUISITION CORPunit 99/99/9999 | $0 | – | -500,000 | -100.0% | -0.47% | – |
| SAGE | Exit | SAGE THERAPEUTICS, INC. | $0 | – | -499,100 | -100.0% | -2.84% | – |
| DVAX | Exit | DYNAVAX TECHNOLOGIES CORP. | $0 | – | -10,895,773 | -100.0% | -4.39% | – |
| REPL | Exit | REPLIMUNE GROUP INC | $0 | – | -2,122,415 | -100.0% | -4.55% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, L.P. #2
- BC SW, LP #3
- Bain Capital Life Sciences Investors II, LLC #4
- Bain Capital Life Sciences Fund II, L.P. #5
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| SAVARA INC | 16 | Q3 2023 | 6.0% |
| X4 PHARMACEUTICALS INC | 16 | Q3 2023 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 15 | Q3 2023 | 20.1% |
| MERSANA THERAPEUTICS, INC. | 14 | Q3 2023 | 8.4% |
| CRINETICS PHARMACEUTICALS, INC. | 14 | Q3 2023 | 5.4% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-05-30 |
| 4 | 2023-05-30 |
| 13F-HR | 2023-05-15 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.